|4Feb 3, 6:55 PM ET

Accardi Mario Alberto 4

4 · Centessa Pharmaceuticals plc · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Centessa (CNTA) CEO Mario Accardi Receives Equity Awards

What Happened
Mario Alberto Accardi, CEO of Centessa Pharmaceuticals plc (CNTA), was awarded equity on Feb 2, 2026 and had a small share disposition for tax withholding. The filing shows: 68,000 restricted share units (RSUs) granted at $0, and 273,000 derivative awards (option-like) granted at $0. Separately, 2,915 shares were disposed on Feb 1 to cover tax withholding at $24.57 per share, totaling approximately $71,622. These were tax-withholding dispositions rather than open-market sales.

Key Details

  • Transaction dates: Feb 1, 2026 (tax withholding disposition); Feb 2, 2026 (grants/awards). Filing date: Feb 3, 2026 (appears timely).
  • Disposition: 2,915 shares withheld/disposed at $24.57 = $71,622 (footnote: shares withheld to cover tax withholding).
  • Awards: 68,000 RSUs (issued under the 2021 Stock Option & Incentive Plan) and 273,000 derivative awards (both reported as acquired at $0).
  • Vesting notes: RSUs vest in four equal annual installments, first vesting 2/2/2027; the derivative award vests 1/48th monthly, first installment vesting 3/2/2026.
  • ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share, per footnote).
  • Shares owned after the transactions are not disclosed in the provided filing excerpt.

Context
The 2,915-share disposition was a routine tax-withholding action tied to equity vesting and should not be read as a traditional sale signaling sentiment. The larger entries are grants—RSUs and a longer-term, monthly-vesting derivative award—so they increase potential future holdings only as they vest; they are not open-market purchases.

Insider Transaction Report

Form 4
Period: 2026-02-01
Accardi Mario Alberto
DirectorChief Executive Officer
Transactions
  • Tax Payment

    Ordinary Shares

    [F1][F2]
    2026-02-01$24.57/sh2,915$71,622175,886 total
  • Award

    Ordinary Shares

    [F1][F3]
    2026-02-02+68,000243,886 total
  • Award

    Share Option (right to buy)

    [F4][F1]
    2026-02-02+273,000273,000 total
    Exercise: $25.19Exp: 2036-02-02Ordinary Shares (273,000 underlying)
Footnotes (4)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
  • [F3]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
  • [F4]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.
Signature
/s/ Raphael Deferiere, attorney-in-fact|2026-02-03

Documents

1 file
  • 4
    wk-form4_1770162921.xmlPrimary

    FORM 4